Hypertension and Dyslipidemia Combined Therapeutic Approaches.
Blood pressure
DASH
Dyslipidemia
Hypertension
PUFA
Statins
Journal
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
ISSN: 1179-1985
Titre abrégé: High Blood Press Cardiovasc Prev
Pays: New Zealand
ID NLM: 9421087
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
19
01
2022
accepted:
11
02
2022
pubmed:
26
3
2022
medline:
3
5
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
Treating blood pressure (BP) alone may provide only limited benefits while it is recommendable to manage the total cardiovascular risk. To date, several studies have shown that concomitant treatment of hypertension and dyslipidemia with non-pharmacological approaches and/or metabolically neutral antihypertensive drugs and statins produce a significantly greater reduction of the risk of developing cardiovascular disease. Thus, in this review article, we summarize the available evidence regarding non-pharmacological and pharmacological approaches with a favourable effect on both BP and lipids.
Identifiants
pubmed: 35334087
doi: 10.1007/s40292-022-00507-8
pii: 10.1007/s40292-022-00507-8
pmc: PMC9050771
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-230Informations de copyright
© 2022. The Author(s).
Références
World Health Organization. Hypertension fact sheet. 2019 [cited 2021 10 October]. https://www.who.int/news-room/fact-sheets/detail/hypertension . Accessed 3 Jan 2022.
Williams B, Masi S, Wolf J, Schmieder RE. Facing the challenge of lowering blood pressure and cholesterol in the same patient: report of a Symposium at the European Society of Hypertension. Cardiol Ther. 2020;9(1):19–34. https://doi.org/10.1007/s40119-019-00159-1 .
doi: 10.1007/s40119-019-00159-1
pubmed: 31933276
pmcid: 7237547
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17018-9 .
doi: 10.1016/S0140-6736(04)17018-9
pubmed: 15364185
Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple risk factor intervention trial research group. JAMA. 1982;248(12):1465–77.
doi: 10.1001/jama.1982.03330120023025
Schwalm JD, McKee M, Huffman MD, Yusuf S. Resource effective strategies to prevent and treat cardiovascular disease. Circulation. 2016;133(8):742–55.
doi: 10.1161/CIRCULATIONAHA.115.008721
2018 Practice Guidelines for the management of arterial hypertension of the European. Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2019;37(2):456. https://doi.org/10.1097/HJH.0000000000002026 .
doi: 10.1097/HJH.0000000000002026
Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014 .
doi: 10.1016/j.atherosclerosis.2019.08.014
Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, Karanja NM, Most-Windhauser MM, Moore TJ, Swain JF, Bales CW, Proschan MA, DASH Research Group. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr. 2001;74(1):80–9. https://doi.org/10.1093/ajcn/74.1.80 .
doi: 10.1093/ajcn/74.1.80
pubmed: 11451721
Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, Tada MT, Lima I, Jannes CE, Krieger JE, Pereira AC, Quintana-Navarro G, Muñiz-Grijalvo O, Díaz-Díaz JL, Alonso R, Mata P, Santos RD. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2021;31(7):2014–22. https://doi.org/10.1016/j.numecd.2021.04.006 .
doi: 10.1016/j.numecd.2021.04.006
pubmed: 34039501
Gibbs J, Gaskin E, Ji C, Miller MA, Cappuccio FP. The effect of plant-based dietary patterns on blood pressure: a systematic review and meta-analysis of controlled intervention trials. J Hypertens. 2021;39(1):23–37. https://doi.org/10.1097/HJH.0000000000002604 .
doi: 10.1097/HJH.0000000000002604
pubmed: 33275398
Rees K, Al-Khudairy L, Takeda A, Stranges S. Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases. Cochrane Database Syst Rev. 2021;2(2):CD013501. https://doi.org/10.1002/14651858.CD013501.pub2 .
doi: 10.1002/14651858.CD013501.pub2
pubmed: 33629376
Cicero AFG, Veronesi M, Fogacci F. Dietary intervention to improve blood pressure control: beyond salt restriction. High Blood Press Cardiovasc Prev. 2021;28(6):547–53. https://doi.org/10.1007/s40292-021-00474-6 .
doi: 10.1007/s40292-021-00474-6
pubmed: 34533781
pmcid: 8590666
Fogacci F, Borghi C, Cicero AFG. Diets, foods and food components’ effect on dyslipidemia. Nutrients. 2021;13(3):741. https://doi.org/10.3390/nu13030741 .
doi: 10.3390/nu13030741
pubmed: 33652643
pmcid: 7996961
Strilchuk L, Cincione RI, Fogacci F, Cicero AFG. Dietary interventions in blood pressure lowering: current evidence in 2020. Kardiol Pol. 2020;78(7–8):659–66. https://doi.org/10.33963/KP.15468 .
doi: 10.33963/KP.15468
pubmed: 32631027
Cicero AFG, Grassi D, Tocci G, Galletti F, Borghi C, Ferri C. Nutrients and nutraceuticals for the management of high normal blood pressure: an evidence-based consensus document. High Blood Press Cardiovasc Prev. 2019;26(1):9–25. https://doi.org/10.1007/s40292-018-0296-6 .
doi: 10.1007/s40292-018-0296-6
pubmed: 30671873
Borghi C, Tsioufis K, Agabiti-Rosei E, Burnier M, Cicero AFG, Clement D, Coca A, Desideri G, Grassi G, Lovic D, Lurbe E, Kahan T, Kreutz R, Jelakovic B, Polonia J, Redon J, Van De Borne P, Mancia G. Nutraceuticals and blood pressure control: a European Society of Hypertension position document. J Hypertens. 2020 May;38(5):799–812. https://doi.org/10.1097/HJH.0000000000002353 .
doi: 10.1097/HJH.0000000000002353
pubmed: 31977574
Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75(1):731–67. https://doi.org/10.1093/nutrit/nux047 .
doi: 10.1093/nutrit/nux047
pubmed: 28938795
Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8(6):2076–88. https://doi.org/10.1039/c7fo00178a .
doi: 10.1039/c7fo00178a
pubmed: 28541356
Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005;25(10):2170–6. https://doi.org/10.1161/01.ATV.0000181761.16341.2b .
doi: 10.1161/01.ATV.0000181761.16341.2b
pubmed: 16100034
Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284(42):28885–95. https://doi.org/10.1074/jbc.M109.052407 .
doi: 10.1074/jbc.M109.052407
pubmed: 19687008
pmcid: 2781434
Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, Luo SH, Fu J, Wen BY, Ren L, Shou JW, Guo F, Chen Y, Gao X, Wang Y, Jiang JD. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015;13:278. https://doi.org/10.1186/s12967-015-0629-3 .
doi: 10.1186/s12967-015-0629-3
pubmed: 26310319
pmcid: 4549888
Qiang X, Xu L, Zhang M, Zhang P, Wang Y, Wang Y, Zhao Z, Chen H, Liu X, Zhang Y. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun. 2016;472(4):603–9. https://doi.org/10.1016/j.bbrc.2016.03.019 .
doi: 10.1016/j.bbrc.2016.03.019
pubmed: 26970305
Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009;296(4):E812-9. https://doi.org/10.1152/ajpendo.90710.2008 .
doi: 10.1152/ajpendo.90710.2008
pubmed: 19176354
Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: a systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25–34. https://doi.org/10.1016/j.phymed.2018.09.212 .
doi: 10.1016/j.phymed.2018.09.212
pubmed: 30466986
Suadoni MT, Atherton I. Berberine for the treatment of hypertension: a systematic review. Complement Ther Clin Pract. 2021;42:101287. https://doi.org/10.1016/j.ctcp.2020.101287 .
doi: 10.1016/j.ctcp.2020.101287
pubmed: 33461163
Mazza A, Schiavon L, Rigatelli G, Torin G, Lenti S. The effects of a new generation of nutraceutical compounds on lipid profile and glycaemia in subjects with pre-hypertension. High Blood Press Cardiovasc Prev. 2019;26(4):345–50. https://doi.org/10.1007/s40292-019-00332-6 .
doi: 10.1007/s40292-019-00332-6
pubmed: 31352663
Mercurio V, Pucci G, Bosso G, Fazio V, Battista F, Iannuzzi A, Brambilla N, Vitalini C, D’Amato M, Giacovelli G, Vaudo G, Schillaci G, Galletti F, Bonaduce D. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Nutr. 2020;39(5):1379–84. https://doi.org/10.1016/j.clnu.2019.06.026 .
doi: 10.1016/j.clnu.2019.06.026
pubmed: 31371114
Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12(8):1113–24. https://doi.org/10.1517/14712598.2012.704014 .
doi: 10.1517/14712598.2012.704014
pubmed: 22780092
Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. BioFactors. 1999;9(2–4):273–84. https://doi.org/10.1002/biof.5520090224 .
doi: 10.1002/biof.5520090224
pubmed: 10416041
Cicero AFG, Fogacci F, Colletti A. Commentary to: “The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. High Blood Press Cardiovasc Prev. 2018;25(1):51–2. https://doi.org/10.1007/s40292-018-0248-1 .
doi: 10.1007/s40292-018-0248-1
pubmed: 29352426
Cicero AF, Colletti A, Fogacci F, Bove M, Rosticci M, Borghi C. Effects of a combined nutraceutical on lipid pattern, glucose metabolism and inflammatory parameters in moderately hypercholesterolemic subjects: a double-blind, cross-over, randomized clinical trial. High Blood Press Cardiovasc Prev. 2017;24(1):13–8. https://doi.org/10.1007/s40292-016-0163-2 .
doi: 10.1007/s40292-016-0163-2
pubmed: 27339779
Tabrizi R, Akbari M, Sharifi N, Lankarani KB, Moosazadeh M, Kolahdooz F, Taghizadeh M, Asemi Z. The Effects of Coenzyme Q10 Supplementation on blood pressures among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. 2018;25(1):41–50. https://doi.org/10.1007/s40292-018-0247-2 .
doi: 10.1007/s40292-018-0247-2
pubmed: 29330704
Sharifi N, Tabrizi R, Moosazadeh M, Mirhosseini N, Lankarani KB, Akbari M, Chamani M, Kolahdooz F, Asemi Z. The effects of coenzyme Q10 supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2018;24(23):2729–42. https://doi.org/10.2174/1381612824666180406104516 .
doi: 10.2174/1381612824666180406104516
pubmed: 29623830
Jorat MV, Tabrizi R, Mirhosseini N, Lankarani KB, Akbari M, Heydari ST, Mottaghi R, Asemi Z. The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17(1):230. https://doi.org/10.1186/s12944-018-0876-4 .
doi: 10.1186/s12944-018-0876-4
pubmed: 30296936
pmcid: 6176512
Sahebkar A, Simental-Mendía LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198–209. https://doi.org/10.1016/j.phrs.2016.01.030 .
doi: 10.1016/j.phrs.2016.01.030
pubmed: 26836888
Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm. 2007;67(2):361–9. https://doi.org/10.1016/j.ejpb.2007.03.010 .
doi: 10.1016/j.ejpb.2007.03.010
pubmed: 17452099
Way TD, Lin HY, Kuo DH, Tsai SJ, Shieh JC, Wu JC, Lee MR, Lin JK. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 2009;57(12):5257–64. https://doi.org/10.1021/jf900730e .
doi: 10.1021/jf900730e
pubmed: 19459711
Shishikura Y, Khokhar S, Murray BS. Effects of tea polyphenols on emulsification of olive oil in a small intestine model system. J Agric Food Chem. 2006;54(5):1906–13. https://doi.org/10.1021/jf051988p .
doi: 10.1021/jf051988p
pubmed: 16506852
Liu W, Wan C, Huang Y, Li M. Effects of tea consumption on metabolic syndrome: a systematic review and meta-analysis of randomized clinical trials. Phytother Res. 2020;34(11):2857–66. https://doi.org/10.1002/ptr.6731 .
doi: 10.1002/ptr.6731
pubmed: 32578328
Park CS, Kim W, Woo JS, Ha SJ, Kang WY, Hwang SH, Park YW, Kim YS, Ahn YK, Jeong MH, Kim W. Green tea consumption improves endothelial function but not circulating endothelial progenitor cells in patients with chronic renal failure. Int J Cardiol. 2010;145(2):261–2. https://doi.org/10.1016/j.ijcard.2009.09.471 .
doi: 10.1016/j.ijcard.2009.09.471
pubmed: 19962201
Lin QF, Qiu CS, Wang SL, Huang LF, Chen ZY, Chen Y, Chen G. A cross-sectional study of the relationship between habitual tea consumption and arterial stiffness. J Am Coll Nutr. 2016;35(4):354–61. https://doi.org/10.1080/07315724.2015.1058197 .
doi: 10.1080/07315724.2015.1058197
pubmed: 26709673
Zhang C, Qin YY, Wei X, Yu FF, Zhou YH, He J. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol. 2015;30(2):103–13. https://doi.org/10.1007/s10654-014-9960-x .
doi: 10.1007/s10654-014-9960-x
pubmed: 25354990
Ried K, Sullivan TR, Fakler P, Frank OR, Stocks NP. Effect of cocoa on blood pressure. Cochrane Database Syst Rev. 2012;8:CD008893. https://doi.org/10.1002/14651858.CD008893.pub2 Update in: Cochrane Database Syst Rev. 2017 Apr 25;4:CD008893.
doi: 10.1002/14651858.CD008893.pub2
Darand M, Hajizadeh Oghaz M, Hadi A, Atefi M, Amani R. The effect of cocoa/dark chocolate consumption on lipid profile, glycemia, and blood pressure in diabetic patients: a meta-analysis of observational studies. Phytother Res. 2021;35(10):5487–501. https://doi.org/10.1002/ptr.7183 .
doi: 10.1002/ptr.7183
pubmed: 34089280
Grassi D, Desideri G, Necozione S, Lippi C, Casale R, Properzi G, Blumberg JB, Ferri C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr. 2008;138(9):1671–6. https://doi.org/10.1093/jn/138.9.1671 .
doi: 10.1093/jn/138.9.1671
pubmed: 18716168
Grassi D, Desideri G, Necozione S, Ruggieri F, Blumberg JB, Stornello M, Ferri C. Protective effects of flavanol-rich dark chocolate on endothelial function and wave reflection during acute hyperglycemia. Hypertension. 2012;60(3):827–32. https://doi.org/10.1161/HYPERTENSIONAHA.112.193995 .
doi: 10.1161/HYPERTENSIONAHA.112.193995
pubmed: 22851734
http://www.brighamandwomens.org/About_BWH/publicaffairs/news/publications/DisplayBulletin.aspx?issueDate=3/28/2014%2012:00:00%20AM . Access 31 Jan 2021.
Butt MS, Sultan MT, Butt MS, Iqbal J. Garlic: nature’s protection against physiological threats. Crit Rev Food Sci Nutr. 2009;49(6):538–51. https://doi.org/10.1080/10408390802145344 .
doi: 10.1080/10408390802145344
pubmed: 19484634
Ried K. Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: a review and meta-analysis. Exp Ther Med. 2020;19(2):1472–8. https://doi.org/10.3892/etm.2019.8374 .
doi: 10.3892/etm.2019.8374
pubmed: 32010325
Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71(5):282–99. https://doi.org/10.1111/nure.12012 .
doi: 10.1111/nure.12012
pubmed: 23590705
Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol. 1998;31(6):904–8. https://doi.org/10.1097/00005344-199806000-00014 .
doi: 10.1097/00005344-199806000-00014
pubmed: 9641475
Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review. J Nutr. 2016;146(2):389S–396S. https://doi.org/10.3945/jn.114.202192 .
doi: 10.3945/jn.114.202192
pubmed: 26764326
Kheirmandparizi M, Keshavarz P, Nowrouzi-Sohrabi P, Hosseini-Bensenjan M, Rezaei S, Kashani SMA, Zeidi N, Tabrizi R, Alkamel A. Effects of garlic extract on lipid profile in patients with coronary artery disease: a systematic review and meta-analysis of randomised clinical trials. Int J Clin Pract. 2021;75(12):e14974. https://doi.org/10.1111/ijcp.14974 .
doi: 10.1111/ijcp.14974
pubmed: 34627133
Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010. Circulation. 2013;128(1):29–41. https://doi.org/10.1161/CIRCULATIONAHA.112.000500 .
doi: 10.1161/CIRCULATIONAHA.112.000500
pubmed: 23817481
pmcid: 4066305
Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG. Antihypertensive drugs and blood lipids: the Oslo study. Br J Clin Pharmacol. 1982;13(Suppl 2):441S–444S. https://doi.org/10.1111/j.1365-2125.1982.tb01954.x .
doi: 10.1111/j.1365-2125.1982.tb01954.x
pubmed: 7104158
pmcid: 1402145
Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;15(2):133–41. https://doi.org/10.7326/0003-4819-122-2-199501150-00010 .
doi: 10.7326/0003-4819-122-2-199501150-00010
Ames R. Effects of diuretic drugs on the lipid profile. Drugs. 1988;36(Suppl 2):33–40. https://doi.org/10.2165/00003495-198800362-00007 .
doi: 10.2165/00003495-198800362-00007
pubmed: 3063504
Ames RP. Antihypertensive drugs and lipid profiles. Am J Hypertens. 1988;1(4 Pt 1):421–7. https://doi.org/10.1093/ajh/1.4.421 .
doi: 10.1093/ajh/1.4.421
pubmed: 2905605
Maitland-van der Zee AH, Klungel OH, Kloosterman JM, Seidell JC, Leufkens HG, de Boer A. The association between antihypertensive drug therapies and plasma lipid levels in the general population. J Hum Hypertens. 2001 Oct;15(10):701–5. https://doi.org/10.1038/sj.jhh.1001197 .
doi: 10.1038/sj.jhh.1001197
pubmed: 11607800
Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49(4):792–8. https://doi.org/10.1161/01.HYP.0000259737.43916.42 .
doi: 10.1161/01.HYP.0000259737.43916.42
pubmed: 17309949
Cicero AFG, Fogacci F, Hernandez AV, Banach M, Lipid, Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003121. https://doi.org/10.1371/journal.pmed.1003121 .
doi: 10.1371/journal.pmed.1003121
pubmed: 32673317
pmcid: 7365413
Correa V Jr, Gus M, Fuchs FD. Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects? Expert Rev Cardiovasc Ther. 2010;8(6):775–9. https://doi.org/10.1586/erc.10.59 .
doi: 10.1586/erc.10.59
pubmed: 20528635
Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10(10):CD011748. https://doi.org/10.1002/14651858.CD011748.pub3 .
doi: 10.1002/14651858.CD011748.pub3
pubmed: 33078867
Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A, Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J. 2004;148(2):285–92. https://doi.org/10.1016/j.ahj.2004.02.003 .
doi: 10.1016/j.ahj.2004.02.003
pubmed: 15308998
Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168(7):721–7. https://doi.org/10.1001/archinte.168.7.721 .
doi: 10.1001/archinte.168.7.721
pubmed: 18413554
pmcid: 4285458
Briasoulis A, Agarwal V, Valachis A, Messerli FH. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens. 2013;15(5):310–20. https://doi.org/10.1111/jch.12081 .
doi: 10.1111/jch.12081
Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation. 2006;114(24):2655–62. https://doi.org/10.1161/CIRCULATIONAHA.106.630194 .
doi: 10.1161/CIRCULATIONAHA.106.630194
pubmed: 17116771
Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–71.
doi: 10.1074/jbc.273.37.24266
Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124(3):335–45. https://doi.org/10.1161/CIRCULATIONAHA.110.985150 .
doi: 10.1161/CIRCULATIONAHA.110.985150
pubmed: 21730307
pmcid: 5357054
Borghi C, Urso R, Cicero AF. Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2017;27(2):115–20.
doi: 10.1016/j.numecd.2016.07.013
Lee S, Yang S, Chang MJ. Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: a systemic review and meta-analysis of randomized studies. PLoS One. 2021;16(11):e0260391. https://doi.org/10.1371/journal.pone.0260391 .
doi: 10.1371/journal.pone.0260391
pubmed: 34818350
pmcid: 8612562
You T, Liu XG, Hou XD, Wang XK, Xie HH, Ding F, Yi K, Zhang P, Xie XD. Effect of statins on blood pressure: analysis on adverse events released by FDA. Clin Exp Hypertens. 2017;39(4):325–9. https://doi.org/10.1080/10641963.2016.1254224 .
doi: 10.1080/10641963.2016.1254224
pubmed: 28513233
Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol. 2009;7(3):330–7. https://doi.org/10.2174/157016109788340659 .
doi: 10.2174/157016109788340659
pubmed: 19601857
Bønaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromsø study. N Engl J Med. 1990;22(12):795–801. https://doi.org/10.1056/NEJM199003223221202 .
doi: 10.1056/NEJM199003223221202
Liu JC, Conklin SM, Manuck SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. Am J Hypertens. 2011;24(10):1121–6. https://doi.org/10.1038/ajh.2011.120 .
doi: 10.1038/ajh.2011.120
pubmed: 21753804
Park Y, Oh SH, Rhee MY. Association between 24-hour ambulatory blood pressure and erythrocyte n-3 polyunsaturated fatty acids in Korean subjects with hypertension. Nutr Res. 2010;30(12):807–14. https://doi.org/10.1016/j.nutres.2010.09.013 .
doi: 10.1016/j.nutres.2010.09.013
pubmed: 21147363
Russo C, Olivieri O, Girelli D, Azzini M, Stanzial AM, Guarini P, Friso S, De Franceschi L, Corrocher R. Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension. J Hypertens. 1995;13(12 Pt 2):1823–6.
pubmed: 8903660
Appel LJ, Miller ER 3rd, Seidler AJ, Whelton PK. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993;28(12):1429–38.
doi: 10.1001/archinte.1993.00410120017003
Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88(2):523–33. https://doi.org/10.1161/01.cir.88.2.523 .
doi: 10.1161/01.cir.88.2.523
pubmed: 8339414
Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20(8):1493–9. https://doi.org/10.1097/00004872-200208000-00010 .
doi: 10.1097/00004872-200208000-00010
pubmed: 12172309
Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20(1):107–20. https://doi.org/10.1177/2047487312437056 .
doi: 10.1177/2047487312437056
pubmed: 22345681
Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885–96. https://doi.org/10.1093/ajh/hpu024 .
doi: 10.1093/ajh/hpu024
pubmed: 24610882
pmcid: 4054797
Leslie KH, McCowan C, Pell JP. Adherence to cardiovascular medication: a review of systematic reviews. J Public Health (Oxf). 2019;41(1):e84–94. https://doi.org/10.1093/pubmed/fdy088 .
doi: 10.1093/pubmed/fdy088
Simon A, Dézsi CA. Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL Study. Adv Ther. 2019;36(8):2010–20. https://doi.org/10.1007/s12325-019-01002-8 .
doi: 10.1007/s12325-019-01002-8
pubmed: 31183780
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0 .
doi: 10.1016/S0140-6736(03)12948-0
pubmed: 12686036
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.
doi: 10.1001/jama.288.23.2998
Messerli FH, Pinto L, Tang SS, Thakker KM, Cappelleri JC, Sichrovsky T, Dubois RW. Impact of systemic hypertension on the cardiovascular benefits of statin therapy–a meta-analysis. Am J Cardiol. 2008;101(3):319–25. https://doi.org/10.1016/j.amjcard.2007.08.033 .
doi: 10.1016/j.amjcard.2007.08.033
pubmed: 18237593
Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel JM, Kuida H. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259(24):3579–86. https://doi.org/10.1001/jama.259.24.3579 .
doi: 10.1001/jama.259.24.3579
pubmed: 3373705